Table 1.
Characteristics of patient cohorts used in the study
| Age (years) | Gender (male/female) | BMI (kg/m2) | Diabetes (%) | ALT (IU/L) | AST (IU/L) | |
| NAFLD cohort | 56 ± 7 | 10/3 | 29.8±3.2 | 69 | 33±23 | 54±36 |
| Hepatitis B cohort | 51±7 | 10/3 | 26.5±2.4 | 38 | 47±50 | 80±64 |
| HCC cohort | 57±7 | 16/1 | 27.5±4.2 | 29 | 55±36 | 65±53 |
| Systemic sclerosis cohort (n=30) |
Age (years) | Gender (male/female) |
BMI (kg/m2) |
Diffuse cutaneous limited SSc | Disease duration (years) |
Heart involvement | Lung involvement | DLCO (%) | Antinuclear antibody-positive | Anticentromere antibody-positive | Antitopoisomerase I antibody-positive |
| 55±14 | 10/20 | 26±3.8 | 12 (40%) | 7.5±4 | 2 (7%) | 11 (37%) | 71.7±17 | 30 (100%) | 11 (37%) | 12 (40%) |
Notes: Viral hepatitis in HCC cohort: HBV-positive, n=8; HCV-negative, n=2; HBV-positive and HCV-positive, n=3.
Data expressed as mean±SD or median (range).
BMI, body mass index; HCC, hepatocellular carcinoma; NAFLD, non-alcoholic fatty liver disease; SSc, systemic sclerosis.